3,380
Participants
Start Date
January 1, 2026
Primary Completion Date
August 15, 2031
Study Completion Date
June 15, 2038
test-directed treatment: allocated treatment will depend on the PAM50 score result (centrally assessed) : chemo-endocrine therapy or endocrine therapy alone
In this experimental arm, the treatment is driven by the score of the Prosigna test. If the score is superior to 60, the patient is considered at hight risk so the patient will receive chemo-endocrine therapy. If the result is under or equal to 60, only endocrine therapy will be prescribed to the patient.
In the control arm, the treatment will be as standard of care : chemo-endocrine therapy
Standard treatment: Chemotherapy followed by endocrine therapy
Institut Gustave Roussy, Villejuif
University of Warwick
OTHER
UNICANCER
OTHER